Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Megan Othus

Showing results (111-120 of 232) with videos related to

Pageof 24
Sort By:
Leukemia Research|February 7, 2018
Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML)Anjali S Advani, Hongli Li, Laura C Michaelis, et al.
Medrxiv : the Preprint Server for Health Sciences|February 6, 2026
Whole Genome Sequencing Informed Patient Personalized Measurable Residual Disease Assays for Acute Myeloid LeukemiaNiveditha Ravindra, Justin Lack, Clifton L Dalgard, et al.
The Lancet. Haematology|July 5, 2016
Infusion of a non-HLA-matched ex-vivo expanded cord blood progenitor cell product after intensive acute myeloid leukaemia chemotherapy: a phase 1 trialColleen Delaney, Filippo Milano, Laura Cicconi, et al.
Leukemia & Lymphoma|March 30, 2017
Flow cytometric demonstration of decrease in bone marrow leukemic blasts after 'Day 14' without further therapy in acute myeloid leukemiaXueyan Chen, Megan Othus, Brent L Wood, et al.
Transplantation and Cellular Therapy|June 24, 2024
Second Allogeneic Hematopoietic Cell Transplantation for Relapsed Adult Acute Myeloid Leukemia: Outcomes and Prognostic FactorsEduardo Rodríguez-Arbolí, Megan Othus, Corentin Orvain, et al.
American Journal of Hematology|February 21, 2024
Relative prognostic value of flow cytometric measurable residual disease before allogeneic hematopoietic cell transplantation for adults with MDS/AML or AMLCorentin Orvain, Naveed Ali, Megan Othus, et al.
JAMA Oncology|December 26, 2025
Immune Checkpoint Inhibitor-Induced Diabetes Across National Cancer Institute Trials That Included PD-1 or PD-L1 AgentsZoe E Quandt, Shanda Finnigan, Vanessa Hill, et al.
Leukemia|April 20, 2022
Utility of the Treatment-Related Mortality (TRM) score to predict outcomes of adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantationLucas C Zarling, Megan Othus, Brenda M Sandmaier, et al.
Haematologica|July 11, 2015
Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOGRoland B Walter, Megan Othus, Bob Löwenberg, et al.
Leukemia & Lymphoma|October 5, 2021
Comparative analysis of infectious complications with outpatient <i>vs.</i> inpatient care for adults with high-risk myeloid neoplasm receiving intensive induction chemotherapyAnna B Halpern, Megan Othus, Nicholas P Howard, et al.
Pageof 24

Showing results (111-120 of 232) with videos related to

Sort By:
Pageof 24
Leukemia Research|February 7, 2018
Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML)Anjali S Advani, Hongli Li, Laura C Michaelis, et al.
Medrxiv : the Preprint Server for Health Sciences|February 6, 2026
Whole Genome Sequencing Informed Patient Personalized Measurable Residual Disease Assays for Acute Myeloid LeukemiaNiveditha Ravindra, Justin Lack, Clifton L Dalgard, et al.
The Lancet. Haematology|July 5, 2016
Infusion of a non-HLA-matched ex-vivo expanded cord blood progenitor cell product after intensive acute myeloid leukaemia chemotherapy: a phase 1 trialColleen Delaney, Filippo Milano, Laura Cicconi, et al.
Leukemia & Lymphoma|March 30, 2017
Flow cytometric demonstration of decrease in bone marrow leukemic blasts after 'Day 14' without further therapy in acute myeloid leukemiaXueyan Chen, Megan Othus, Brent L Wood, et al.
Transplantation and Cellular Therapy|June 24, 2024
Second Allogeneic Hematopoietic Cell Transplantation for Relapsed Adult Acute Myeloid Leukemia: Outcomes and Prognostic FactorsEduardo Rodríguez-Arbolí, Megan Othus, Corentin Orvain, et al.
American Journal of Hematology|February 21, 2024
Relative prognostic value of flow cytometric measurable residual disease before allogeneic hematopoietic cell transplantation for adults with MDS/AML or AMLCorentin Orvain, Naveed Ali, Megan Othus, et al.
JAMA Oncology|December 26, 2025
Immune Checkpoint Inhibitor-Induced Diabetes Across National Cancer Institute Trials That Included PD-1 or PD-L1 AgentsZoe E Quandt, Shanda Finnigan, Vanessa Hill, et al.
Leukemia|April 20, 2022
Utility of the Treatment-Related Mortality (TRM) score to predict outcomes of adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantationLucas C Zarling, Megan Othus, Brenda M Sandmaier, et al.
Haematologica|July 11, 2015
Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOGRoland B Walter, Megan Othus, Bob Löwenberg, et al.
Leukemia & Lymphoma|October 5, 2021
Comparative analysis of infectious complications with outpatient <i>vs.</i> inpatient care for adults with high-risk myeloid neoplasm receiving intensive induction chemotherapyAnna B Halpern, Megan Othus, Nicholas P Howard, et al.
Pageof 24